CellKey is developing Glycoprotein analytics pipeline and data repository(SpAC9) and providing Mass Spec. based Glycoprotein Analysis and Glycoprotein Biomarker discovery and validation services

Our SpAC9 service is the most comprehensive glycoprotein analysis solution in the market providing massive data analytics functionalities with most comprehensive experimental data repository

—Namyong Lee, CEO

PharmAbcine is a leading biotech company contributing to human health and wellbeing by providing innovative therapeutic antibodies to patients with unmet needs. Since the last decade, the company has acquired extensive expertise through research collaboration and clinical studies alongside its partners (including Sanofi, MSD, and Roche). Moreover, the company’s research and development workforce has grown to over 50 personnel, more than half of whom hold a master’s degree or higher. The company also has its own antibody library called HuPhage, consisting of over 10 billion different antibodies.

Pharma organizations from all over the world have already begun placing their bets on combination therapies using PharmAbcine’s drug candidates to achieve successful outcomes for cancer treatment

Dr. Jin-San Yoo, Founder and CEO

ROKIT Healthcare is a global regenerative solutions company committed to providing an effective autologous organ regeneration platform using its proprietary 3D bio-fabrication technologies. In the life sciences research market, we supply clean-bench 3D bioprinters "INVIVO"​ as laboratory tools to advance research in tissue engineering, material science, and regenerative medicine. In the clinical market, it is in the development of 3D printing-based clinical platforms that provide personalized therapy in the areas of skin, cartilage, retina, and heart patch regeneration. In summary, ROKIT Healthcare is committed to accelerating the translation of bioprinting technology from the bench to the clinic for improved patient care.

Abbisko Therapeutics is based in Shanghai Zhangjiang Science City. It is a small molecule novel medication research and development company. The firm is dedicated to helping patients by researching and developing innovative treatments for illnesses that have no effective therapy at home or abroad. The company's founders and management team include national "Thousand Talents" and senior professionals. Years of R&D management experience at significant worldwide and local pharmaceutical businesses, including leading and participating in the development of many clinical and commercialised novel products.

By collecting long-term fundamental scientific research results-based protein drug development technologies, The business created the first antibody biosimilar authorised in the nation in 2006, the yihurodo. Bioreactors, protein and antibody drug design methodologies, antibody-drug synthesis efficiency cell technology. They have consistently improved mass manufacturing antibody drug technology and drug effectiveness and pharmacological property analyses. We now have unequalled technical prowess, extensive R&D skills, and manufacturing infrastructure that can compete with huge global pharmaceutical businesses.

Immvira was founded in Shenzhen China in May of 2015 by Prof. Grace Zhou, formerly a Research Associate Professor at the University of Chicago, and a few other virologists and immunologists as well. The mission of the company is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer-specific immune factors or chemotherapeutic agents that can be delivered intratumorally or systemically.

JuiceInnov8 is a deep tech startup with a focus on the food biotechnology space. It develops sugar reduction technology with our non-GM microbes for the juice industry to build a better & healthier 100% juice with less sugar & lower calories. At JuiceInnov8, it cultivate and screen through hundreds of microbes from nature to find the perfect natural sugar reducer for the specific type of juice under controlled conditions & selected pathways. Its technology platform will enable juice producers to customize the range of natural sugar reduction from mildly sweet - less sugar to sugar-free - zero calories

Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care and where inflammation plays a central role. The Company’s portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

They are a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests. Their story began in early 2000 when their founders pioneered a highly sensitive, specific, and robust detection technology for microRNA (miRNA), the smallest genetic material ever found in humans and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, we decided to bring our technology from lab to clinic.

Modalis is an expert in Genome editing technology, a modality that evolves CRISPR and treats with gene switching. Modalis is an original name that the Company has chosen to hope Company’s proprietary gene modulation technology, CRISPR-GNDM, to be a new modality (therapeutic technology) to assist patients fighting with genetic disorders. It is the key to the treatment of genetic diseases, and the logo of the company name expresses “a gene switch” becoming the target of the CRISPR-GNDM technology.

Nanogen Pharma is a leading company that is doing research and development of active Biopharmaceutical ingredients (APIs), and specific therapeutic injections in the Asia Pacific region, based on advances in recombinant DNA and protein technologies. Nanogen offers a variety of gene-to-therapy biopharmaceuticals for the treatment of hepatitis B, hepatitis C, anemia due to chronic renal failure, oncology, etc. Its departments and facilities are integrated into the area of 15 000 square meters, located in Saigon Hi-tech Park Ho Chi Minh City Vietnam. It researches, develops, manufactures and markets a wide range of therapeutic injection products under strict compliance with current GMP and tight QC/QA procedures.

At OliPass, scientists from diverse fields are constantly working together to find the cures for all diseases. With its innovative OliPass PNA platform technology, its goal is to make the highest quality of science affordable and accessible, so that everyone around the world can enjoy a happy, healthy life. OliPass is dedicated to providing safe and feasible options for healthy aging.

OriCiro is a ​pioneer in cell-free synthesis and amplification of genome-scale large DNA for synthetic biology. OriCiro offers groundbreaking, cell-free technologies of large DNA assembly and amplification that can effectively replace the conventional E. coli cloning process. OriCiro® Cell-Free Cloning System is an innovative tool enabling cell-free assembly and amplification of circular DNA molecules without E. coli transformation and culture. This product can not only streamline your workflow dramatically but also widen the scope of your genetic engineering techniques.

The firm was built on the protein expression and antibody production technologies pioneered by the University of Tokyo's Laboratories for Systems Biology and Medicine (LSBM). They started off with antibody drug research and development. Their high-affinity antibodies were created by using LSBM's membrane protein manufacturing technology. A new screening technique may concurrently find highly functioning antibodies with properties different from those obtained from standard animal vaccination. For therapeutic applications, our strategy combines these two antibody technologies with “seeds” discovery technology

PharmAbcine is a leading biotech company contributing to human health and wellbeing by providing innovative therapeutic antibodies to patients with unmet needs

PHASE Scientific is a high-growth biotech company with a mission to inspire a new state of health. Headquartered in Hong Kong with locations in Southern California and China's Greater Bay Area, it provides novel diagnostic tools and services for cancer and infectious diseases with our proprietary technologies.v

PlexBio Co., Ltd. is an ISO-certified company that designs, develops, and produces IVD products and instruments. PlexBio now has offices in Jiangsu Province, China, and an Innovative Technology Center in San Francisco, USA. PlexBio is now listed on Taiwan's developing stock market. In order to manage growing healthcare expenditures and an expanding test menu, clinical and research laboratories must evaluate labour, sample volume, time, and maintenance costs. PlexBio intends to deliver a cutting-edge multiplexing platform based on proprietary Precision Image Code (Code) MicroDisc technology.

With development grounded in close observation of the natural world, Spiber’s Brewed Protein™ materials are produced through a fermentation process that utilizes sugars and microbes, rather than petrochemical or animal-derived raw materials. With their potential for mainstay industrial use, Spiber believes that Brewed Protein™ materials represent a compelling contribution towards its shared endeavor to create a more sustainable future for humanity and nature, both now and for generations to come.

ThinkCyte’s mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enables the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.

TurtleTree is a biotech company that’s using cell-based technology to create sustainable food and dairy. Nonetheless, we earnestly believe that what we do extends beyond the dining table and into the heart of humanity. At its core, it seeks to uplift the world by providing a new generation of nutrition that’s better for the planet, better for the animals, and better for people everywhere.